The UK MHRA strengthened its warning on GLP-1 receptor agonists and pancreatitis in January 2026 (19 deaths since 2007 among ~1.6 million users). Brazil followed. Headlines duly alarmed. But a critical look at the evidence tells a different story: this is a case study in how pharmacovigilance systems generate noise that gets mistaken for signal.

1. What the RCTs Actually Show: Nothing

The major cardiovascular outcome trials — LEADER (liraglutide), SUSTAIN-6 (semaglutide), SELECT (semaglutide), SURPASS (tirzepatide) — consistently show pancreatitis rates that are comparable to or lower than placebo:

• LEADER: 0.4% treatment vs 0.5% placebo
• SELECT: 0.2% treatment vs 0.3% placebo
• Network meta-analysis of 102,257 participants: RR 0.96 (95% CI 0.31–3.00)

These trials were not powered to detect rare events, but the direction of the point estimates is consistently away from harm. When your safety signal points in the opposite direction from your hypothesis across >100,000 randomized participants, you do not have a safety signal.

2. The 2025 Meta-Analysis: A Lesson in Confounding

The most recent meta-analysis (62 RCTs, 2025) reported an overall RR of 1.44 (95% CI 1.09–1.89) — seemingly alarming. But the stratified analysis tells the real story:

• With background medications: RR 1.85 (95% CI 1.05–3.26) — significant
• Without background medications: RR 0.81 (95% CI 0.43–1.55) — null, trending protective

The "increased risk" disappears entirely when you remove confounding by concomitant therapy. This is not a drug effect — it is a polypharmacy effect in a high-risk population. Numerous studies in the meta-analysis reported zero events in both arms, making absolute risk calculations essentially meaningless.

3. The Confounding Problem: You Are Screening the Wrong Denominator

Obesity and type 2 diabetes are independent risk factors for acute pancreatitis. The baseline incidence of pancreatitis in the GLP-1 target population is significantly elevated before any drug is introduced. When the UK reports 1,300 pancreatitis cases among 1.6 million GLP-1 users over 18 years, that is a rate (~0.08%) that needs to be compared against the expected background rate in obese/diabetic patients — not against zero.

Thousands of people are hospitalized with pancreatitis in Britain every year regardless of GLP-1 use. The MHRA data cannot distinguish coincidence from causation because it lacks a denominator and a control group.

4. Biological Plausibility Favors Biliary Mechanism, Not Direct Toxicity

GLP-1 receptors are expressed on pancreatic acinar cells, which provides theoretical grounds for concern. But the experimental evidence does not support direct toxicity:

• Animal models: GLP-1 receptor activation in mice did not increase severity of experimentally induced pancreatitis; it modulated anti-inflammatory genes (SOCS-3)
• Enzyme elevations: GLP-1 RAs cause asymptomatic lipase increases (~31%) and amylase increases (~7%) that resolve on discontinuation and do not predict clinical pancreatitis
• The real mechanism is probably biliary: GLP-1 RAs slow biliary motility → biliary sludge → gallstones → obstructive pancreatitis. This is a mechanical, indirect pathway — not pancreatic toxicity

The biological story is not "GLP-1 inflames the pancreas." It is "GLP-1 slows the gallbladder, and rapid weight loss forms gallstones, and gallstones cause pancreatitis." These are different problems requiring different solutions (ursodeoxycholic acid prophylaxis, not drug withdrawal).

5. Spontaneous Reporting Is Systematically Broken for This Question

The MHRA Yellow Card and ANVISA systems suffer from well-documented biases that are maximally activated here:

• Weber effect: Reporting rates spike after market introduction regardless of true incidence
• Stimulated reporting (notoriety bias): Media coverage of GLP-1 side effects prompts clinicians to report pancreatitis they would otherwise attribute to obesity/diabetes/gallstones
• No denominator: Spontaneous reports cannot calculate incidence rates
• No control group: You cannot compare against the expected background rate
• Confounding by indication: Every patient receiving GLP-1 has risk factors for pancreatitis by definition

The MHRA warning was based on spontaneous reports from an uncontrolled database in a high-risk population after extensive media coverage. This is the textbook scenario in which pharmacovigilance generates false positives.

Bottom Line

The GLP-1/pancreatitis signal is a pharmacovigilance artifact. Randomized data from >100,000 participants show no increased risk. The positive 2025 meta-analysis result disappears when you control for background medications. The biological mechanism points to biliary complications from weight loss, not direct pancreatic toxicity. And the spontaneous reporting data that triggered regulatory warnings is systematically biased toward false positives in exactly this clinical scenario.

None of this means pancreatitis never occurs in GLP-1 users — it does, because it occurs in obese diabetic patients at baseline. But the evidence does not support the claim that GLP-1 drugs cause pancreatitis. The regulatory warnings are responding to noise, not signal.

Research powered by BIOS.